Patient Savings Card

  • FIBRICOR savings card

    Save With The FIBRICOR®
    Patient Savings Card

    Pay as little as $15 for 30 days*
    *Limitations apply. reimbursement limited to $200 per month.






    Patient instructions:
    • Get a valid prescription for FIBRICOR or Fenofibric Acid Tablets. Ask your doctor if FIBRICOR is right for you.
    • Register and download your FIBRICOR Patient Savings Card below.
    • Fill your prescription by taking your prescription and the Card to your pharmacy.
    • Many eligible commercially insured patients may receive their prescription for as little as $15.*

    *Program eligibility and restrictions apply. This offer is only valid for FIBRICOR, manufactured for Athena Bioscience LLC, or Fenofibric Acid, manufactured for Palmetto Pharmaceuticals, Inc. No substitutions permitted.

    Fill in form below to receive a printable FIBRICOR Patient Savings Card.
    All fields are required.
  • Athena respects individual privacy and values the confidence of our customers. The information pertaining to you that we collect will be used in accordance with our Privacy Statement. By providing your email address, you agree and acknowledge that you would like to receive information from Athena related to FIBRICOR and the FIBRICOR Patient Savings Card, including site updates, education, and other FIBRICOR products and services. If you later wish to opt out from receiving this information, you may click on the included opt-out link in future communications.
  • The “Copay Savings Card” constitutes an offer subject to the below “Offer Terms, Conditions, and Patient Eligibility Criteria.” This offer is not insurance. Quantity limits may apply.
  • Each patient redeeming the Copay Savings Card acknowledges and agrees as follows:
    1. The offer constituted by the Card is only made to, and can only be accepted by, a patient who is 18 years of age or older, with a valid prescription for Fibricor® Tablets (“Fibricor®”), manufactured for Athena, or Fenofibric Acid Tablets (“Fenofibric Acid”), manufactured for Palmetto Pharmaceuticals Inc. (“Palmetto”) when filled by a pharmacist at a participating pharmacy, and duly dispensed to the patient. No substitutions are permitted.
    2. Depending on applicable insurance coverage, eligible patients may receive their prescription for Fibricor® or Fenofibric Acid, manufactured for Athena or Palmetto, for $15.00 or less. Each patient accepting this offer should ask the fulfilling pharmacist to determine any applicable copay discount. Athena makes no promise, guaranty, covenant, representation, warranty or other undertaking in regard to the actual savings, if any, that a patient may receive for Fibricor® or Fenofibric Acid, whether in consequence of the Card or otherwise.
    3. This offer is subject to a maximum limit of $200.00 per month, to be applied to any copay obligation that an eligible patient may have. Patient out-of-pocket expenses may vary.
    4. This offer is not valid for and may not be used by: patients enrolled in Medicare (including Part D), Medicaid, or other federal or state programs (including state pharmaceutical assistance programs, and for Puerto Rico, the Government Health Insurance Plan, formerly La Reforma de Salud, and for each any successor program); patients enrolled in private indemnity or HMO insurance plans or pharmacy benefit programs that in each instance reimburse the patient for the entire cost of a prescription drug; or patients who are Medicare-eligible and enrolled in an employ¬er-sponsored health plan or prescription drug benefit program for retirees.
    5. This offer is valid for those cash-paying patients not otherwise excluded by another provision of this offer.
    6. This offer is only good for the United States of America (including its States, territories and possessions, including Puerto Rico), at participating eligible retail, specialty, or mail-order pharmacies.
    7. This offer is void wherever prohibited by law or where it is taxed or restricted.
    8. The Card is limited to one per person and is not transferable. The selling, purchasing, trading, or counterfeiting of the Card is prohibited by law. The Card has no cash value and cannot be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription.
    9. This offer neither constitutes, nor is a substitute for, health insurance. Each patient is responsible for applicable taxes, if any.
    10. Athena may rescind, revoke, amend, modify or restate this offer at any time and from time to time without notice.
    11. Certain information related to or arising from your use of the Card will be shared with Athena as the Card’s sponsor, together with Athena’s affiliates, including: the date your prescription is filled; the quantity of product dispensed to you by the pharmacist; and the amount of copay to be paid with the Card. Please see Athena’s Privacy Policy, www.athenabioscience.com/patientprivacy, for more information.
    12. At the time of acceptance, you are eligible for this offer, have read and understood it, and are bound by and agree to abide by its restrictions, terms, and conditions.
    By using this offer, you and your pharmacist understand and agree to comply with these eligibility terms of use.

    *Program eligibility and restrictions apply. This offer is only valid for FIBRICOR, manufactured for Athena Bioscience LLC, or Fenofibric Acid, manufactured for Palmetto Pharmaceuticals Inc. No substitutions permitted. Void wherever prohibited by law, taxed, or restricted. Subject to the OFFER TERMS, CONDITIONS, AND PATIENT ELIGIBILITY REQUIREMENTS. Please see full prescribing information at www.fibricor.com.
  • This field is for validation purposes and should be left unchanged.

FIBRICOR® (fenofibric acid) Important Safety Information

FIBRICOR® is contraindicated in patients with severe renal impairment including those on dialysis, with active liver disease including primary biliary cirrhosis and unexplained persistent liver function abnormalities and with gallbladder disease. FIBRICOR is also contraindicated in nursing mothers and patients with hypersensitivity to fenofibric acid or fenofibrate.

The most commonly reported adverse reactions (>2% and at least 1% greater than placebo) are abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis.

Fenofibrate can increase serum transaminases. Monitor liver tests, including ALT, periodically during therapy. In addition, myopathy and rhabdomyolysis have been reported in patients taking fenofibrate. Fibrates increase the risk for myopathy and have been associated with rhabdomyolysis. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal failure, or hypothyroidism. Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever. Creatine phosphokinase (CPK) levels should be assessed in these patients. Treatment should be discontinued if markedly elevated CPK levels occur or myopathy/myositis is suspected or diagnosed. Fenofibrate can reversibly increase serum creatinine levels. The clinical relevance of these findings is unknown. Patients with renal impairment and those at risk for renal insufficiency should be periodically monitored. Fenofibrates may increase cholesterol excretion into the bile, leading to risk of cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. Discontinue treatment if gallstones are found.

You are encouraged to report adverse reactions to Athena Bioscience, LLC at 1-833-874-2664 or to the FDA: 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the accompanying Full Prescribing Information.